H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating and $7.00 price target on Fate Therapeutics (NASDAQ: FATE).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments